KALA BIO, Inc. — Director's Dealing 2025

Jan 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: KALA BIO, Inc. (KALA)
CIK: 0001479419
Period of Report: 2025-01-06

Reporting Person: Bazemore Todd (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-06	Common Stock	A	10100	—	Acquired		Direct
2025-01-06	Common Stock	S	1993	$7.63	Disposed		Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-06	Stock Option (right to buy)	$7.53	A	45200	Acquired	2035-01-05	Common Stock (45200)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1	Indirect

Footnotes

F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028.

F2: Includes 64,324 unvested RSUs.

F3: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5: This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer.